Collaborations, Upcoming Seminar, Clinical Trial Results, Data Presentation Schedule - Research Reports on AstraZeneca, Illumina, Novartis, Lilly and Alexion

NEW YORK, August 26, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding AstraZeneca PLC (NYSE: AZN), Illumina Inc. (ILMN: ILMN), Novartis AG (NYSE: NVS), Eli Lilly and Company (NYSE: LLY) and Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5971-100free.

AstraZeneca PLC Research Reports 

On August 21, 2014, AstraZeneca PLC (AstraZeneca) announced that it has entered into a partnership deal with Illumina, Inc. (Illumina), to create its next generation sequencing (NGS) platform for companion diagnostic tests applicable through AstraZeneca's oncology portfolio. The Company plans to utilize Illumina's technology to a novel companion diagnostic test in pivotal studies for one of its investigational oncology compounds, which is expected to accelerate the procedure of clinical trials. Ruth March, Vice President, Personalized Healthcare & Biomarkers at AstraZeneca, said, "This partnership has the potential to deliver an unprecedented amount of clinical information from a single test. Illumina's technology will inform doctors about the molecular make-up of their patients' tumours, enabling them to match medicines to the drivers of disease." The full research reports on AstraZeneca are available to download free of charge at:

http://www.analystsreview.com/Aug-26-2014/AZN/report.pdf

Illumina Inc. Research Reports 

As per the Events Calendar of Illumina Inc. (Illumina), the Company is scheduled to host Columbus Illumina User Group Meeting on August 28, 2014 from 8:00 a.m. to 5:00 p.m. at the Blackwell Inn & Conference Center. According to the Illumina, the scientists who are scheduled to speak at the seminar are: Patrick Schloss, PhD, Associate Professor, Department of Microbiology & Immunology - University of Michigan Medical School; Francesca Luca, PhD, Center for Molecular Medicine & Genetics - Wayne State University and few others. According to Illumina, the Company's presentation at the aforesaid event will cover a broad range of applications and attendees can attend sessions in the areas of Optimization of the Sequencing Workflow or Bioinformatics. The full research reports on Illumina are available to download free of charge at:

http://www.analystsreview.com/Aug-26-2014/ILMN/report.pdf

Novartis AG Research Reports 

On August 20, 2014, Novartis AG (Novartis) reported that it has entered into a worldwide exclusive licensing agreement with the Global Alliance for TB Drug Development (TB Alliance) for compounds to fight tuberculosis (TB) that have been discovered at the Novartis Institutes for Tropical Diseases (NITD). As per the agreement, NITD will completely transfer its TB research and development program to TB Alliance, which will take financial and operational responsibility for continued research, development, approval and distribution of compounds in the portfolio. The agreement includes a novel class of drugs called indolcarboxamides, which are effective against drug sensitive and multi-resistant strains of TB. Mark C. Fishman, President of Novartis Institutes for BioMedical Research, stated "TB Alliance is well placed to take our discoveries and compounds through development for the benefit of patients with TB." The full research reports on Novartis are available to download free of charge at:

http://www.analystsreview.com/Aug-26-2014/NVS/report.pdf

Eli Lilly and Company Research Reports 

On August 21, 2014, Eli Lilly and Company (Lilly) reported top-line outcomes from its pivotal Uncover studies in average-to-acute plaque psoriasis, which disclosed that its Investigational medicine ixekizumab was statistically better to etanercept and placebo on all skin clearance measures in Phase 3 studies. According to the Company, the results of the trials highlighted that the patients treated with both dosing regimens of ixekizumab had considerably higher levels of skin clearance compared to placebo and to etanercept at the 12-week endpoint. David Ricks, Senior Vice President at Lilly, and President at Lilly Bio-Medicines, said, "These data are important for people suffering from moderate-to-severe plaque psoriasis, as up to 41 percent of those treated with ixekizumab were able to achieve clear skin at week 12, with just one injection per dose." The full research reports on Lilly are available to download free of charge at:

http://www.analystsreview.com/Aug-26-2014/LLY/report.pdf

Alexion Pharmaceuticals, Inc. Research Reports 

On August 13, 2014, Alexion Pharmaceuticals, Inc. (Alexion) announced that it will present the latest data from multiple studies of asfotase alfa in pediatric patients with hypophosphatasia (HPP) at the American Society for Bone and Mineral Research (ASBMR) 2014 Annual Meeting, scheduled from September 12- September 15, 2014. According to Alexion, abstract summarizing the asfotase alfa studies were published on August 13, 2014 at the ASBMR website and has been made available to participants of the conference and ASBMR members. The meeting will include a latest abstract of survival data in pediatric patients with HPP at high risk of death who were treated with asfotase alfa, along with outcomes from two studies in patients with perinatal, infantile and juvenile HPP who were remedied with asfotase alfa for up to three years. The full research reports on Alexion are available to download free of charge at:

http://www.analystsreview.com/Aug-26-2014/ALXN/report.pdf

About Analysts Review

We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.

===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

http://www.AnalystsReview.com

SOURCE Analysts Review